Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

BRAF binds CTNNB1 and KRAS. 2 / 2

| 2

➶

sparser

"In particular, CTNNB1 mutations were consistently associated with the constitutive activation of the RAF/MEK/ERK pathway by either KRAS (n=4) or BRAF (n=3) concurrent mutations."

26797410

➶

sparser

"In particular, CTNNB1 mutations were consistently associated with the constitutive activation of the RAF/MEK/ERK pathway by either KRAS (n=4) or BRAF (n=3) concurrent mutations, in keeping with the notion that CTNNB1 mutations are early events in CRC carcinogenesis. xref Conversely, our data confirm that the occurrence of SMAD4 mutations (2.1%) is a late event. xref In fact, in our study 64.3% of SMAD4 mutations occurred in combination with other alterations."

26797410

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...